Skip to main content

Table 2 Experiment 1: losses after intravenous injection of Biferonex®, relative concentrations and actual doses after direct subcutaneous injection at various dose levels

From: Biases affecting injected doses of an experimental drug during clinical trials

Dose level [MIU] (Biferonex® HSA-free) Losses after intravenous injection Relative concentration (direct subcutaneous injection) Actual dose [MIU] (direct subcutaneous injection)
  Median Range Median Range Median Range
0.5 −4.3 % 22.3 % 93 % 34 % 0.57 0.13
1.0 −10.6 % 31.9 % 115 % 29 % 1.10 0.02
4.0 −7.3 % 15.6 % 94 % 16 % 4.38 0.10
  1. Losses observed after injection through the infusion line (intravenous) versus direct injection (subcutaneous) of Biferonex® HSA-free at different dose levels. A negative value represents an apparent gain. Relative concentrations are expressed with reference to nominal levels